↓ Skip to main content

Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study

Overview of attention for article published in BMC Cancer, August 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

twitter
48 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study
Published in
BMC Cancer, August 2017
DOI 10.1186/s12885-017-3505-0
Pubmed ID
Authors

Amy Skitch, Seema Mital, Luc Mertens, Peter Liu, Paul Kantor, Lars Grosse-Wortmann, Cedric Manlhiot, Mark Greenberg, Paul C Nathan

Abstract

Anthracycline-induced cardiac toxicity is a cause of significant morbidity and early mortality in survivors of childhood cancer. Current strategies for predicting which children are at greatest risk for toxicity are imperfect and diagnosis of cardiac injury is usually made relatively late in the natural history of the disease. This study aims to identify genomic, biomarker and imaging parameters that can be used as predictors of risk or aid in the early diagnosis of cardiotoxicity. This is a prospective longitudinal cohort study that recruited two cohorts of pediatric cancer patients at six participating centres: (1) an Acute Cohort of children newly diagnosed with cancer prior to starting anthracycline therapy (n = 307); and (2) a Survivor Cohort of long-term survivors of childhood cancer with past exposure to anthracycline (n = 818). The study team consists of three collaborative cores. The Genomics Core is identifying genomic variations in anthracycline metabolism and in myocardial response to injury that predispose children to treatment-related cardiac toxicity. The Biomarker Core is identifying existing and novel biomarkers that allow for early diagnosis and prognosis of anthracycline-induced cardiac toxicity. The Imaging Core is identifying echocardiographic and cardiac magnetic resonance (CMR) imaging parameters that correspond to early signs of cardiac dysfunction and remodeling and precede global dysfunction and clinical symptoms. The data generated by the cores will be combined to create an integrated risk-prediction model aimed at more accurate identification of children who are most susceptible to anthracycline toxicity. We aim to identify genomic risk factors that predict risk for anthracycline cardiotoxicity pre-exposure and imaging and biomarkers that facilitate early diagnosis of cardiac injury. This will facilitate a personalized approach to identifying at-risk children with cancer who may benefit from cardio- protective strategies during therapy, and closer surveillance and earlier initiation of medications to preserve heart function after cancer therapy. NCT01805778 . Registered 28 February 2013; retrospectively registered.

Twitter Demographics

The data shown below were collected from the profiles of 48 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 81 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 11 14%
Researcher 9 11%
Student > Bachelor 9 11%
Student > Ph. D. Student 7 9%
Professor 7 9%
Other 23 28%
Unknown 15 19%
Readers by discipline Count As %
Medicine and Dentistry 40 49%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Biochemistry, Genetics and Molecular Biology 3 4%
Unspecified 2 2%
Computer Science 2 2%
Other 10 12%
Unknown 20 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2017.
All research outputs
#918,924
of 20,984,993 outputs
Outputs from BMC Cancer
#116
of 7,523 outputs
Outputs of similar age
#21,286
of 288,193 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 20,984,993 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,523 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,193 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them